This study was designed to evaluate whether the revised 2010 Tumour Node Metastasis (TNM) staging system could lead to a more accurate prediction of the prognosis of renal cell carcinoma (RCC) patients. A total of 1216 patients who had undergone radical nephrectomy or partial nephrectomy for RCC from 2003 to 2011 were enrolled. All of the patients had pathologically confirmed clear cell RCC (ccRCC). All cases were staged by both the 2002 and 2010 TNM staging systems after pathological review, and survival data were collected. Univariate and multivariate Cox regression models were used to evaluate cancer-specific survival (CSS) and progression-free survival (PFS) after surgery. Continuous variables, such as age and tumour diameter, were calculated as mean values and standard deviations (s.d.) or as median values. Survival was calculated by the Kaplan-Meier method, and the log-rank test assessed differences between groups. Statistically significant differences in CSS and PFS were noted among patients in T3 subgroups using the new 2010 staging system. Therefore, the revised 2010 TNM staging system can lead to a more accurate prediction of the prognosis of ccRCC patients. However, when using the revised 2010 staging system, we found that more than 92% of patients (288/313) with T3 tumours were staged in the T3a subgroup, and their survival data were not significantly different from those of patients with T2b tumours. In addition, T2 subclassification failed to independently predict survival in RCC patients.
INTRODUCTION
Renal cell carcinoma (RCC) is the most common malignancy of the kidney, and its occurrence is increasing in both men and women. RCC is found worldwide, with its highest incidence in developed countries. 1 It is estimated that approximately 37.7 men and 16.6 women per 100 000 Chinese people are diagnosed with RCC every year. 2 The Tumour Node Metastasis (TNM) staging system is widely used to define the anatomic extent of the disease, to indicate the prognosis, to classify the tumour for a treatment plan, to evaluate the results of different studies and to facilitate the exchange of information. An older (sixth edition) TNM staging system for RCC, from 2002, has been described previously. 3 With the revision of its pathological features in 2010 (seventh edition), stage T2 in the new staging system was divided into two subgroups according to the tumour size (T2a .7 cm and f10 cm; T2b .10 cm). Furthermore, the new staging system directly reclassified the adrenal gland invasion from T3a to T4, and the renal vein invasion from T3b to T3a. These changes were evidenced by the fact that the reassignment of pathological features to specific stages could more accurately predict the cancer-specific survival (CSS) and progression-free survival (PFS) associated with an increased T stage. 4, 5 Using the 2002 and 2010 TNM staging systems, this retrospective study aimed to compare the accuracy of prognosis prediction in 1216 patients who underwent radical nephrectomy or partial nephrectomy for RCC from 2003 to 2011. All patients were pathologically confirmed to have clear cell RCC (ccRCC).
MATERIALS AND METHODS

Subjects/patients
A total of 1216 patients with ccRCC confirmed by pathological examination were enrolled from 2003 to 2011 in three hospitals (Department of Urology in the First Affiliated Hospital of Nanjing Medical University, Nanjing, China; the Affiliated Hospital of Medical College Qingdao University, Qingdao, China; and the Third Affiliated Hospital of Soochow University, Changzhou, China). Patients' information, such as age and sex, and tumour characteristics, such as tumour diameter, stage and Fuhrman grade, were obtained from the hospital databases. We recorded the tumour stage according to the 2002 staging system as originally documented in the reports and then reassigned the tumour stage according to the revised 2010 staging system.
Follow-up and evaluation
The duration of follow-up was calculated from the date of the operation to the date of death or last follow-up. Exact data, such as the causes of death of each patient, were acquired from the patients' family members or hospital records if the patient had been followed up or had died. During follow-up, patients were reviewed every 6 months with clinical and radiological assessments such as chest and abdomen computed tomography scan when necessary. The last follow-up occurred during December 2011, during which the CSS and PFS were measured. The Response Evaluation Criteria in Solid Tumours evaluation standard was introduced to analyse PFS. In cases with target metastatic lesions, the progression of disease was evaluated when the maximum diameter of the target lesion increased to 20% greater than that of the smallest lesion recorded after the beginning of treatment or when one or more new lesions developed. In cases with non-target metastatic lesions, progression of disease was evaluated when one or more new lesions developed and/or when the non-target lesions showed definite progress.
Statistical analysis
Continuous variables, such as age and tumour diameter, were calculated as mean6standard deviation (s.d.) and were compared by t-test. Differences in survival times according to disease stage were estimated using the Kaplan-Meier method and were compared using the logrank test. P,0.05 was considered statistically significant, and all statistical tests were two-sided. All of the statistical analyses were performed with SPSS 17.0 (SPSS Inc, Chicago, IL, USA).
RESULTS
The patients' clinical and pathological characteristics are listed in Table 1 . The mean age of the patients was 57.5611.5 years. In total, 794 patients (65.3%) were male, and 422 patients (34.7%) were female. The mean tumour size of all patients was 6.263.7 cm. At a median follow-up of 35.0 months, 96 (7.9%) patients had died of the disease, while 119 (9.8%) patients demonstrated disease progression.
The N and M stagings did not change substantially between the 2002 and 2010 systems, so we compared the T stage distribution according to the 2002 and 2010 TNM staging systems ( Table 1) . Based on the 2002 staging system, there were 503, 173, 178, 114, 203, 13 and 32 patients in stages T1a, T1b, T2, T3a, T3b, T3c and T4, respectively. Kaplan-Meier curves showed that the cumulative CSS and PFS were statistically significantly different between consecutive increases in T stage (both P,0.001, Figure 1a and 1b) . We then reclassified tumour T stage according to the revised 2010 T staging system. The number of patients in stages T1 and T2 remained the same, but the T2 stage was divided into two subgroups, with 116 and 62 patients in stages T2a and T2b, respectively. We noted an increase in the number of patients in stage T3a, from 114 to 288, and a decrease in the number of patients in stage T3b, from 203 to 12, because patients with renal vein invasions were reclassified; the number of patients in stage T3c remained the same. We also noted that 17 patients were reclassified to stage T4 according to the new staging system because of adrenal gland invasion. After reclassification, we found that the cumulative CSS and PFS demonstrated statistically significant, measurable differences between consecutive increases in T stage according to the 2010 staging system (both P,0.001, Figure 1c and 1d).
As shown in Table 2 , T stage, tumour grade, and metastasis status were correlated with CSS in the univariate analysis. However, in the multivariate analysis of potential prognostic factors for patients with ccRCC, only T stage and metastasis status could be confirmed as significant independent prognostic factors correlated with CSS. Similar results were noted in the univariate and multivariate analyses for PFS (data not shown).
According to the 2002 staging system, we found that the prognosis of patients with T3b tumours was better than that of patients with T3a tumours, as the cumulative CSS was statistically significantly different between these two groups (P,0.001, Figure 2a ). Although the differences in cumulative PFS were not significantly different, there was still a similar trend between these two groups (P50.065, Figure 2b ). However, when we re-analysed these data by using the 2010 staging system, we found that the prognosis of patients with T3b tumours was worse than that of patients with T3a tumours; both the cumulative CSS and PFS were statistically significantly different between these two groups (both P,0.001, Figure 2c and 2d).
In the 2010 TNM staging system, patients with renal vein invasions were reclassified as T3a, which resulted in 201 patients being downstaged to T3a. The Kaplan-Meier analysis showed that patients whose disease was downstaged had significantly better survival than those who remained classified as T3b (P,0.001 for CSS, Figure 3a ; P50.001 for PFS, Figure 3b ), indicating that this reclassification better demonstrates the survival of patients with diverse outcomes. Further, 17 patients were shifted from T3a to T4 because adrenal gland invasion was reclassified into stage T4. Similarly, the Kaplan-Meier analysis showed that patients reclassified as T4 had poorer survival than patients whose T3a classification did not change (P,0.001 for CSS, Figure 3c ; P,0.001 for PFS, Figure 3d ).
According to the 2010 new T staging system, the T2 group was divided into two subgroups, with 116 patients in stage T2a and 62 patients in T2b. Applying the Kaplan-Meier analysis to compare these two subgroups, we found no significant differences in CSS and PFS between the T2a and T2b subgroups (P50.364 for CSS, Figure 4a ; P50.093 for PFS, Figure 4b ). Furthermore, when we excluded patients with lymph node or distant metastases, we found that there was no significant difference in CSS or PFS between these two subgroups (P50.900 for CSS, Figure 4c ; P50.251 for PFS, Figure 4d ).
Provided that the major revision in the 2010 TNM staging system was in the T3 staging, we focused on the effect of this update on survival outcomes. According to the 2002 staging system, there were 114, 203 and 13 patients in stages T3a, 3b and 3c, respectively. When reclassified by the 2010 version, we noticed that most of patients with T3 tumours were grouped into the T3a stage (92.01%), while the Kaplan-Meier analysis did not show that patients with T3a tumours had poorer survival than those with T2b tumours (P50.203 for CSS, Figure 5a ; P50.604 for PFS, Figure 5b) . Therefore, we considered whether it was necessary to divide the T3a stage into several subgroups to more accurately predict the prognosis. To validate this hypothesis, we divided the T3a group into subgroups. First, we used a 7-cm cutoff to analyse PFS and CSS and found that the results did not show any significant difference unless the cutoff was increased to 10 cm. Thus, we divided the T3a group into two subgroups according to the diameter of the tumour (subgroup1 f10 cm, subgroup2 .10 cm), and the Kaplan-Meier analysis showed that patients with subgroup2 tumours had poorer survival rates than T2b and subgroup1 patients (CSS rate50.040 and 0.017 for subgroup2 vs. T2b and subgroup1, respectively, Figure 5c ; PFS rate50.222 and 0.0478 for subgroup2 vs. T2b and subgroup1, respectively, Figure 5d) . However, the survival data were not significantly different between subgroup1 and T2b patients (CSS and PFS rate50.582 and 0.681, respectively, Figure 5c and 5d). Second, we divided the T3a group into three subgroups according to the extension of tumour invasion (tumour invading the perirenal and/or renal sinus fat as subgroup1, tumour grossly invading the renal vein as subgroup2, and tumour invading the perirenal and/or renal sinus fat and renal vein as subgroup3) and found that patients with subgroup3 tumours had poorer survival than patients in subgroup1 and subgroup2 (all P,0.001 for CSS and PFS, Figure 5e and 5f). However, the survival data were not significantly different between subgroup1 and subgroup2 (Figure 5e and 5f) . Furthermore, we found that patients with subgroup3 tumours had better survival than those in the T3b, T3c or T4 groups (P50.016 for PFS, P50.079 for CSS) (Figure 6a and 5b) .
DISCUSSION
Most researchers believe that the difference in the incidence of ccRCC between developed countries and developing countries might be based on different levels of diagnosis, autopsy rates and environmental factors. The influence of the patient's ethnic background on RCC is not as evident as in other tumours, such as prostate cancer. Thus, the TNM New staging system for RCC better reflects prognosis C Qin et al 552 Figure 2 These Kaplan-Meier curves show that the prognosis of patients with T3b was better than that of patients with T3a tumours according to the 2002 staging system (a: P,0.001 for CSS; b: P50.065 for PFS). In the 2010 staging system, the prognosis of patients with T3b was worse than that of patients with T3a tumours (c: P,0.001 for CSS; d: P,0.001 for PFS). CSS, cancer-specific survival; PFS, progression-free survival. New staging system for RCC better reflects prognosis C Qin et al 553 Figure 3 Survival curves of patients with diseases downstaged from T3b to T3a and of those with diseases remaining in T3b (a: P,0.001 for CSS; b: P50.001 for PFS). Survival curves of patients with diseases upstaged from T3a to T4 and of those with disease remaining in T3a (c: P,0.001 for CSS; d: P,0.001 for PFS). CSS, cancerspecific survival; PFS, progression-free survival. New staging system for RCC better reflects prognosis C Qin et al 554 staging system of RCC is suitable for worldwide application. Our present study showed that the revised TNM staging system of RCC effectively stratified the patient's risk of cancer progression and reflected the prognosis of our cohort of 1216 patients with ccRCC. Many studies have attempted to improve the accuracy of the TNM staging system, and previous studies have demonstrated that T3 tumours comprise a heterogeneous group of tumours that vary in prognosis. 6 Many studies have found that tumours involving the direct ipsilateral adrenal gland can be recognized as predictive of a poorer prognosis, as those tumours act more aggressively than tumours involving the perirenal or renal sinus fat. These researchers have suggested that the direct ipsilateral adrenal gland involvement in Figure 5 According to the 2010 staging system, the Kaplan-Meier curves did not show significant differences between the CSS and PFS rates for the T2b and T3a subgroups (a: P50.203 for CSS; b: P50.604 for PFS). We divided the T3a group into two subgroups according to the diameter of the tumour (subgroup1 f10 cm, subgroup2 .10 cm) and found that patients with subgroup2 tumours had poorer survival than T2b and subgroup1 patients (CSS rate50.040 and 0.017 for subgroup2 vs. T2b and subgroup1, respectively, c; PFS rate50.222 and 0.0478 for subgroup2 vs. T2b and subgroup1, respectively, d) (c, d: 1, T2b; 2, T3a subgroup1; 3, T3a subgroup2; 4, T3b). Finally, we divided the T3a group into three subgroups according to the extent of the tumour invasion (tumour invading the perirenal and/or renal sinus fat as subgroup1, tumour grossly extending into the renal vein as subgroup2, tumour invading the perirenal and/or renal sinus fat and renal vein as subgroup3) and found that patients with subgroup3 tumours had poorer survival than subgroup1 and subgroup2 patients (all CSS and PFS rates ,0.001, e and f) (e, f: 1, T2b; 2, T3a subgroup1; 3, T3a subgroup2; 4, subgroup3). CSS, cancer-specific survival; PFS, progression-free survival.
New staging system for RCC better reflects prognosis C Qin et al 555 patients with pT3a in the old T staging system should be reclassified to pT4, as such tumours exhibit the same aggressive clinical behaviours as those extending beyond the Gerota's fascia. [7] [8] [9] [10] Therefore, in the revised 2010 TNM staging system, direct adrenal gland invasion was reclassified into the T4 stage. Our results were consistent with those of previous studies and supported this revision. In our study, 17 cases were upstaged from T3a to T4 according to the new staging system and demonstrated significantly poorer survival than the cases that remained in the T3a group. The improvements evidenced by this reclassification came about mainly as a consequence of the inclusion of adrenal invasion, a strong adverse prognostic factor, in the T4 disease category.
In previous studies, both Novara et al. 5 and Kim et al. 11 showed that there was a significantly different survival rate between the T3a and T3b subgroups according to the revised 2010 staging system. Kaplan-Meier plots showed a significant difference in survival between the T3a and T3b subgroups (log-rank, P50.03), indicating that the 2010 TNM staging system could accurately distinguish survival between T3a and T3b tumours. Moreover, 191 patients with T3b tumours were downstaged to T3a under the new staging system. Those patients who were shifted from T3b to T3a had significantly better prognoses than those who were not shifted.
However, we failed to demonstrate any significant difference in survival between the T2a and T2b subgroups. Our data were similar to those of Waalkes's study, 12 which examined 579 patients with stage T2 RCC tumours. However, Novara et al.
5 studied nearly 590 stage T2 RCC tumours and found significant a difference between the T2 subgroups. Therefore, further larger-scale studies should be conducted to confirm the significant difference between the outcomes of these two groups.
Furthermore, in our study, more than 92% of patients (288/313) in the T3 stage were classified into the T3a subgroup. Veeratterapillay et al. 13 found that 88% of their patients were classified into the T3a group, and they considered this to be a potential weakness of the revised TNM staging system, as the aim of any staging system providing prognostic data is to divide the patient population into groups bearing different outcomes. If almost all of the patients are divided into one group or subgroup, then the staging system could be perceived as having limited practical value. In addition, the survival of patients with T3a tumours was similar to the survival observed in T2b patients in our cohort. Thus, we considered whether it was necessary to divide the T3a group into different subgroups to predict the prognosis more accurately. We analysed the PFS and CSS with a cutoff of 7 cm, but the results did not show any significant difference unless the cutoff was increased to 10 cm. After dividing the T3a stage into two subgroups according to the diameter of the tumour (subgroup1 f10 cm, subgroup2 .10 cm), we found that patients with subgroup2 tumours had poorer survival than T2b and subgroup1 patients. Gofrit et al.
14 analysed the prognosis of patients with T3a tumours according to the 2002 staging system and found that tumour size was an important factor affecting outcomes in T3a tumours, a conclusion that was corroborated by our data. Then, we divided the T3a group into three subgroups, according to the extent of tumour invasion (tumour invading the perirenal and/or renal sinus fat as subgroup1, tumour grossly extending into the renal vein as subgroup2, and tumour invading the perirenal and/ or renal sinus fat and renal vein as subgroup3), and found that patients with subgroup3 tumours had poorer survival than those in subgroup1 and subgroup2. These data suggest that more accurate classifications of T3a stages might more effectively predict the prognosis. Our sample size was relatively small and most likely of inadequate power to detect any significant changes in outcomes between patients with renal vein invasion and those with perirenal fat invasion. Novara et al.
5 studied the outcomes of 1059 patients with T3a tumours and found that there was no difference between the outcomes of patients with renal vein invasions and those with perinephric fat invasions. Our data were therefore in line with a larger study that supported the updated 2010 T3a classification.
CONCLUSIONS
To summarize, the revised 2010 TNM staging system better reflects the prognosis of patients with ccRCC in eastern China. However, some of the substages identified by the staging system have overlapping prognoses, and other substages include patients with heterogeneous outcomes. Further larger studies are needed to resolve these limitations in the T2 and T3a staging system. The staging system requires modifications, especially in the T3a staging system, to reduce the number of patients classified as T3a. In the present study, it was necessary to divide the T3a group into subgroups according to the tumour size (f or .10 cm) or to the extent of invasion to more accurately predict the prognosis. This feasible modification should be validated by larger samples in the future.
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